A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma |
| |
Authors: | E Gabriela Chiorean Tomislav Dragovich John Hamm Virginia K Langmuir Stewart Kroll Donald T Jung Alan B Colowick George F Tidmarsh Patrick J Loehrer |
| |
Institution: | (1) Indiana University Cancer Center, 535 Barnhill Drive, Room 414, Indianapolis, IN 46202, USA;(2) Arizona Cancer Center, Tucson, AZ, USA;(3) Norton Health Care, Louisville, KY, USA;(4) Threshold Pharmaceuticals, Redwood City, CA, USA |
| |
Abstract: | Absract
Purpose To evaluate safety and pharmacokinetics and to establish the maximum tolerated dose of glufosfamide when administered in combination
with gemcitabine in advanced solid tumors.
Methods This Phase 1 dose-escalation study evaluated the combination of glufosfamide + gemcitabine in patients with advanced solid
tumors. Cohorts of three to six patients were treated with glufosfamide doses from 1,500 to 4,500 mg/m2 IV over 4 h on Day 1 and gemcitabine 1,000 mg/m2 IV over 30 min on Days 1, 8 and 15 of every 28-day cycle. Detailed PK sampling was performed on days 1 and 8 of the first
two cycles.
Results Nineteen patients were enrolled. Two patients had dose-limiting toxicity: Grade 3 fatigue at 2,500 mg/m2 and Grade 4 thrombocytopenia at 4,500 mg/m2. Five patients completed six cycles and one patient remained on study for ten cycles. Two patients discontinued for adverse
events. Grade 3/4 neutropenia and thrombocytopenia occurred in seven patients and five patients, respectively. The CrCL fell
below 60 mL/min in two patients. There was one unconfirmed partial response and 10 of 19 (52.6%) patients had stable disease
or better at 8 weeks and three patients had continuing stable disease at 24 weeks. Pharmacokinetic analyses suggest no interaction
between glufosfamide and gemcitabine.
Conclusion Phase I data indicate that full dose glufosfamide (4,500 mg/m2) can be given safely in combination with gemcitabine. A Phase II study in patients with pancreatic adenocarcinoma is ongoing.
Presented in part at the 2006 ASCO Gastrointestinal Symposium. Research supported by Threshold Pharmaceuticals, Inc. |
| |
Keywords: | Pancreatic cancer Phase I Combination chemotherapy Gemcitabine Glufosfamide Targeted therapy |
本文献已被 PubMed SpringerLink 等数据库收录! |
|